{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:25:03Z","timestamp":1758050703308,"version":"3.44.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jcjo.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T20:47:16Z","timestamp":1651092436000},"page":"e210-e213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bilateral primary squamous cell carcinoma of the conjunctiva"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-6578","authenticated-orcid":false,"given":"Nishaant","family":"Bhambra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9089-8683","authenticated-orcid":false,"given":"Bryan","family":"Arthurs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel N.","family":"Burnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-0123","authenticated-orcid":false,"given":"Christian","family":"El-Hadad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2022.04.001_bib0001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/IIO.0b013e3181928fb9","article-title":"Squamous cell carcinoma of the eyelid and conjunctiva","volume":"49","author":"Mehta","year":"2009","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.jcjo.2022.04.001_bib0002","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/IOP.0000000000001798","article-title":"Prognostic factors for orbital exenteration, local recurrence, metastasis, and death from disease in conjunctival squamous cell carcinoma","volume":"37","author":"El-Hadad","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.jcjo.2022.04.001_bib0003","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjo.2022.04.001_bib0004","unstructured":"Government of Canada. Libtayo - notice of compliance with conditions - qualifying notice. www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/notice-compliance\/conditions\/libtayo-notice-compliance-conditions-218718.html. Accessed October 3, 2021."},{"key":"10.1016\/j.jcjo.2022.04.001_bib0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ophtha.2020.09.027","article-title":"Immunotherapy for conjunctival squamous cell carcinoma with orbital extension","volume":"128","author":"Demirci","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2022.04.001_bib0006","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.18553\/jmcp.2021.21164","article-title":"Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma","volume":"27","author":"Paul","year":"2021","journal-title":"J Managed Care Spec Pharm"},{"key":"10.1016\/j.jcjo.2022.04.001_bib0007","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","article-title":"Ocular adverse events with immune checkpoint inhibitors","volume":"31","author":"Fang","year":"2019","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.jcjo.2022.04.001_bib0008","unstructured":"US Food and Drug Administration. FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma. Accessed October 3, 2021."}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000841822200120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000841822200120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:11:06Z","timestamp":1757794266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000841822200120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S000841822200120X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2022.04.001","relation":{},"ISSN":["0008-4182"],"issn-type":[{"type":"print","value":"0008-4182"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bilateral primary squamous cell carcinoma of the conjunctiva","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}